Genmab — Februar 2020
-
Vi har været under massivt attack. Beklager nedetiden.
-
Tak for jeres donationer, Det meste går til skærpelsen af sikkerhed her på sitet.
-
Netop. Sikkerheden er strammet gevaldigt. Angrebet i dag fandt dog en vej ind gennem vores firewall.
-
Gid det var så vel bibob.
Tak til alle som bidr -
ager.
-
TV trial in Japan fully recruited. Not a large trial, but important as it is a large market for cervical cancer https://clinicaltrials.gov/ct2/history/NCT03913741?A=5&B=6&C=merged#StudyPageTop
-
-
B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches https://www.nature.com/articles/s41375-020-0734-z
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind